Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038881 · ClinicalTrials.gov registry record · Phase 2
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
A Phase 2 study of Smallpox, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 12
- Study locations
NCT02038881 is a Phase 2 study of Smallpox that has completed, run by Bavarian Nordic. The registered enrollment target is 87 participants, below the 131,039-participant average among 7 other Smallpox trials with a reported enrollment target (100% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT02038881, a Phase 2 study of Smallpox, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 12
- Study locations
Study Summary
The main purpose of this clinical trial is to generate additional safety data in a highly immunocompromised population. HIV-infected persons are considered excellent candidates to represent the highly immunocompromised population for enrolment in this trial. Additionally, the immune system's response (protection against smallpox as measured by the amount of antibodies produced) following injections of MVA-BN® smallpox vaccine will be evaluated. All participants in this trial will be randomly and evenly assigned to one of three groups to receive two, three or four injections. Group 1 will receive the standard regime consisting of one dose at each vaccination time point, Group 2 will receive two doses at each vaccination time point and Group 3 will receive a booster vaccination 12 weeks after the standard vaccination schedule with MVA-BN® smallpox vaccine. Participation in the trial is scheduled to last up to 75 weeks.
Conditions Studied
Interventions
- BIOLOGICAL IMVAMUNE®
Study Locations (12)
Florida
- Infectious Disease Associats of NW Florida Center for Prevention and Treatment of Infections Infectious Diseases Associates of NW FL - Pensacola
- Rowan Tree Medical - Wilton Manors
PR
- Clinical Research Puerto Rico, Inc. - San Juan
- Fundacion de Investigacion - San Juan
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- Health for Life Clinic Little Rock - Little Rock
California
- Quest Clinical Research - San Francisco
District of Columbia
- Dupont Circle Physicians Group - Washington D.C.
Illinois
- University of Illinois - Chicago - Chicago
Iowa
- University of Iowa Departments of Internal Medicine and Microbiology University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2014-04-28 |
| Est. Completion | 2017-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02038881
The ClinicalTrials.gov registry entry for NCT02038881 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131,039-participant average among 7 other Smallpox trials with a reported enrollment target (100% lower). The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smallpox appearing as the primary indexed condition, and to 1 intervention - of which IMVAMUNE® is the first listed.
NCT02038881 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Florida, PR, Alabama.
Frequently Asked Questions
What is clinical trial NCT02038881 about?
NCT02038881 is a clinical study titled "Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection". The main purpose of this clinical trial is to generate additional safety data in a highly immunocompromised population. HIV-infected persons are considered excellent candidates to represent the highly immunocompromised population for enrolment in this trial. Additionally, the immune system's respons...
What is the current status of trial NCT02038881?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2014-04-28. Estimated completion is 2017-05-10.
What conditions does trial NCT02038881 study?
This clinical trial studies the following conditions: Smallpox.
What interventions are being tested in trial NCT02038881?
The interventions under investigation include: IMVAMUNE® (BIOLOGICAL).
Who is sponsoring clinical trial NCT02038881?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02038881 being conducted?
This trial has 12 study locations across Alabama, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smallpox
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
ACTIVE NOT RECRUITING · Phase 2
-
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
COMPLETED · Phase 2
-
Dryvax Dilution-Prev Vacc Adults
COMPLETED · Phase 2
-
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
COMPLETED
-
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
COMPLETED
-
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.